title: In prostate cancer, low adiponectin levels are not associated with insulin resistance.
abstract: OBJECTIVE
  Adiponectin, an adipose tissue-derived hormone with insulin-sensitizing effect, has been inversely associated with several hormonally dependent malignancies. Prostate cancer is associated with low levels of adiponectin, which have been proposed as an independent risk factor for this malignancy. Aim of this study was to examine whether hypoadiponectinaemia in prostate is associated with insulin resistance.
  
  
  METHODS
  Plasma samples and covariate data in the context of a case-control study of 300 Greek men were evaluated including 75 patients with prostate cancer, 75 patients with benign prostatic hyperplasia (BPH) and 150 age-matched healthy controls.
  
  
  RESULTS
  Patients with prostate cancer had significantly lower plasma adiponectin levels compared with the other two groups, that is BPH patients and healthy controls (7.4 ± 5 ng/mL vs. 11.5 ± 6.4 ng/mL and 12.8 ± 8 ng/mL, respectively). On the other hand, no statistically significant differences were found between patients with prostate cancer and the other two groups for both HOMA-IR and QUICKI (P-value = 0.551). As expected, in all three groups, the levels of adiponectin correlated negatively with HOMA-IR (rho = -0.214, P-value = 0.006), QUICKI (rho = 0.214, P-value = 0.006) and insulin levels (rho = 0.942, P-value < 0.001).
  
  
  CONCLUSIONS
  In spite of what would have been expected from the relevant literature, our data suggest that the hypoadiponectinaemia in prostatic cancer does not appear to be associated with insulin resistance.
authors.affiliation: First Department of Internal Medicine, National and Kapodestrian University of Athens, School of Medicine, 'Laiko' General Hospital, Athens, Greece.|Department of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Crete, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Michalakis
authors.affiliation: Department of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Crete, Greece.
authors.forename: Maria
authors.initials: M
authors.lastname: Venihaki
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
authors.forename: Christos
authors.initials: C
authors.lastname: Mantzoros
authors.affiliation: Second Department of Pediatrics & Diabetes Center, P & A Kyriakou Children's Hospital, Athens, Greece.
authors.forename: Andriani
authors.initials: A
authors.lastname: Vazaiou
authors.affiliation: Endocrine Department, E. Venizelou Hospital, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Ilias
authors.affiliation: Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Gryparis
authors.affiliation: Department of Clinical Chemistry, School of Medicine, University of Crete, Heraklion, Crete, Greece.
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Margioris
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D016022:Case-Control Studies; D005215:Fasting / Q000097:blood; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood*; D012044:Regression Analysis
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D007328:Insulin
keywords: Adiponectin; HOMA-IR; QUICKI; biomarkers; epidemiology; insulin resistance; prostate cancer